Regeneron scientists have developed novel methods for assigning functions to genes and creating preclinical disease models. This strategy, which comprises a variety of technology platforms, has been grouped under the heading "VelociGene®."

Realizing the Value of the Genome Sequencing Projects

The sequencing of the human genome identified tens of thousands of genes, many of them previously unknown. Unfortunately, genomic sequence alone does not explain the function of many of these novel genes. Therefore, defining the genes' biological activities and potential roles in diseases and health remains the major limiting step in fully realizing the value of genome sequencing projects.

Rapid, Precise, High-throughput Creation of Any Genetic Modification

VelociGene is a proprietary, high-throughput process, using automated systems to make any genetic modification in mouse embryonic stem (ES) cells, allowing rapid production of mouse ES cells that can be used to create mouse models of human diseases and elucidate gene function. Utilizing this technology together with VelociMouse®, Regeneron scientists are able to generate genetically modified mice directly from ES cells without the need for chimeras or breeding. With VelociGene, it is also possible to introduce more sophisticated changes, such as replacing a mouse gene, either partially or entirely, with its human counterpart, thus generating an invaluable resource for drug development studies.

National Institutes of Health Selects VelociGene

VelociGene has been selected by the National Institutes of Health (NIH) as part of its Knockout Mouse Project, Regeneron will use VelociGene to take aim at 3,500 of the most difficult genes to target and to advance the NIH project.

Highlights